Form 4: Cartesian Therapeutics Director Timothy A. Springer Reports Stock Purchase

Director Timothy A. Springer reports purchasing 8,016 shares of Cartesian Therapeutics (RNAC) at an average price of $12.7205 on August 12, 2024.

Summary

• On August 12, 2024, Timothy A. Springer, a director and 10% owner of Cartesian Therapeutics, Inc. (RNAC), purchased 8,016 shares of common stock.
• The purchase was made at a weighted average price of $12.7205 per share, with individual prices ranging from $12.48 to $13.05.
• Following the transaction, Springer directly owns 4,379,899 shares and indirectly owns 11,509 shares through his wife and 1,927,630 shares through TAS Partners LLC.
• Springer disclaims beneficial ownership of shares held by TAS Partners LLC except to the extent of his pecuniary interest.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of a stock purchase by a director. The purchase itself is a mildly positive signal, but the filing is simply a procedural requirement.

Positives

• A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure required by the SEC for insiders who trade in their company's stock. It provides transparency to the market regarding the transactions of company executives and directors.

Stakeholder Impact

• The stock purchase by a director could have a slightly positive impact on shareholder sentiment.

Key Dates